The use of desmopressin in mild hemophilia A

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 7, 2010, Pages 615-619

  Franchini, Massimo ^a   Zaffanello, Marco ^b   Lippi, Giuseppe ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

acquired hemophilia A; carriers; desmopressin; mild hemophilia A; tachyphylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 8C; DESMOPRESSIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

BLEEDING; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; GENE MUTATION; HEMOPHILIA A; HETEROZYGOTE; HUMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW;

DEAMINO ARGININE VASOPRESSIN; HEMOPHILIA A; HUMANS; TREATMENT OUTCOME; VON WILLEBRAND DISEASE, TYPE 1;

EID: 77958186825     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32833c2bb5     Document Type: Review

References (45)

1. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. Haemophilia 2000; 6 (Suppl. 1):60-67.
2. Franchini M. The use of desmopressin as a hemostatic agent. Am J Hematol 2007; 82:731-735.
3. Rodeghiero F, Castaman G, Mannucci PM. Clinical indications for desmopressin (DDAVP) in congenital and acquired von Willebrand disease. Blood Rev 1991; 5:155-161.
4. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet 1977; 1:869-872. (Pubitemid 8079684)
5. Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84:160-174. (Pubitemid 30601459)
6. Castaman G. Desmopressin for the treatment of haemophilia. Haemophilia 2008; 14 (Suppl 1):15-20.
7. Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanisms of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975; 30:81-93.
8. Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339:245-253.
9. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 2003; 1:682-689.
10. Haberichter SL, Shi Q, Montgomery RR. Regulated release of VWF and FVIII and the biologic implications. Pediatr Blood Cancer 2006; 46:547-553.
11. Mariani G, Ciavarella N, Mazzucconi MG, Antoncecchi S, Solinas S, Ranieri P, et al. Evaluation of the effectiveness of DDAVP in surgery and bleeding episodes in hemophilia and von Willebrand disease: a study of 43 patients. Clin Lab Haematol 1984; 6:229-238. (Pubitemid 15180587)
12. de la Fuente B, Kasper CK, Rickles FR, Hoyer LW. Response of patients with mild and moderate hemophilia A and von Willebrand disease to treatment with desmopressin. Ann Intern Med 1985; 103:6-14.
13. Revel-Vilk S, Blanchette VS, Sparling C, Stain AM, Carcao MD. DDAVP challenge tests in boys with mild/moderate haemophilia A. Br J Haematol 2002; 117:947-951. (Pubitemid 34639260)
14. Lethagen S. Desmopressin in mild hemophilia A: indications, limitations, efficacy, and safety. Semin Thromb Hemost 2003; 29:101-106. (Pubitemid 36250271)
15. Villar A, Jimenez-Yuste V, Quintana M, Hernandez-Navarro F. The use of haemostatic drugs in haemophilia: desmopressin and antifibrinolytic agents. Haemophilia 2002; 8:189-193. (Pubitemid 35277133)
16. Nolan B, White B, Smith J, O'Reilly C,McMahon C, Fitzpatrick B, Smith OP. Desmopressin: therapeutic limitations in children and adults with inherited coagulation disorders. Br J Haematol 2000; 109:865-869. (Pubitemid 30609770)
17. Mannucci PM, Vicente V, Alberca I, Sacchi E, Longo G, Harris AS, Lindquist A. Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: pharmacokinetics and factor VIII responses. Thromb Haemost 1987; 58:1037-1039.
18. Lethagen S, Harris AS, Sjorin E, Nilsson IM. Intranasal and intravenous administration of desmopressin: effect on FVIII/vWF, pharmacokinetics and reproducibility. Thromb Haemost 1987; 58:1033-1036.
19. Lethagen S, Harris AS, Nilsson IM. Intranasal desmopressin (DDAVP) by spray in mild hemophilia A and von Willebrand's disease type I. Blut 1990; 60:187-191. (Pubitemid 20114913)
20. Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 2009; 82:87-93.
21. Smith TJ, Gill JC, Ambroso DR, Hathaway WE. Hyponatremia and seizures in young children given DDAVP. Am J Hematol 1989; 31:199-202.
22. Bond L, Bevan D. Myocardial infarction in a patient with hemophilia treated with DDAVP. N Engl J Med 1988; 318:121. (Pubitemid 18029309)
23. Virtanen R, Kauppila M, ItäläM. Percutaneous coronary intervention with stenting in a patient with haemophilia A and an acute myocardial infarction following a single dose of desmopressin. Thromb Haemost 2004; 92:1154-1156. (Pubitemid 39545543)
24. Franchini M, Mannucci PM. Co-morbidities and quality of life in elderly persons with hemophilia. Br J Haematol 2010; 148:522-533.
25. Castaman G, Lethagen S, Federici AB, Tosetto A, Goodeve A, Budde U, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood 2008; 111:3531-3539.
26. Castaman G, Mancuso ME, Giacomelli SH, Tosetto A, Santagostino E, Mannucci PM, Rodeghiero F. Molecular and phenotypic determinants of response to desmopressin in adult patients with mild hemophilia A. J Thromb Haemost 2009; 7:1824-1831.
27. Riccardi F, Rivolta GF, Franchini M, Pattacini C, Neri TM, Tagliaferri A. Characterization of a novel mutation in the F8 promoter region associated with mild hemophilia A and resistance to DDAVP therapy. J Thromb Haemost 2009; 7:1234-1235.
28. Warrier AI, Lusher JM. DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease. J Pediatr 1983; 102:228-233.
29. Ghirardini A, Chistolini A, Tirindelli MC, Di Paolantonio T, Iacopino G, Mariani P, et al. Clinical evaluation of subcutaneously administered DDAVP. Thromb Res 1988; 49:363-372.
30. Chistolini A, Dragoni F, Ferrari A, La Verde G, Arcieri R, Ege Mohamud A, Mazzucconi MG. Intranasal DDAVP: Biological and clinical evaluation in mild factor VIII deficiency. Haemostasis 1991; 21:273-277.
31. Rose EH, Aledort LM. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. Ann Intern Med 1991; 114:563-568.
32. Rodeghiero F, Castaman G, Mannucci PM. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A. Thromb Haemost 1996; 76:692-696. (Pubitemid 26388171)
33. Seremetis SV, Aledort LM. Desmopressin nasal spray for hemophilia A and type I von Willebrand disease. Ann Intern Med 1997; 126:744-745. (Pubitemid 27184055)
34. Leissinger V, Becton D, Cornell C, Cox Gill J. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia 2001; 7:258-266. (Pubitemid 32471959)
35. Lethagen S, Ragnarson Tennvall G. Self-treatment with desmopressin intranasal spray in patients with bleeding disorders: effect on bleeding symptoms and socioeconomic factors. Ann Hematol 1993; 66:257-260. (Pubitemid 23179050)
36. Venkateswaran L, Wilimas JA, Jones DJ, Nuss R. Mild hemophilia in children: prevalence, complications, and treatment. J Pediatr Hematol Oncol 1998; 20:32-35. (Pubitemid 28119753)
37. Franchini M, Favaloro EJ, Lippi G. Mild hemophilia A. J Thromb Haemost 2010; 8:421-432.
38. Hay CRM, Ludlam CA, Colvin BT, Hill FG, Preston FE, Wasseem N, et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A: UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998; 79:762-766.
39. Robbins D, Kulkarni R, Gera R, Scott-Emuakpor AB, Bosma K, Penner JA. Successful treatment of high titer inhibitors in mild hemophilia A with avoidance of factor VIII and immunosuppressive therapy. Am J Hematol 2001; 68:184-188. (Pubitemid 32983207)
40. Aledort LM. Can we prevent inhibitors in mild and moderate factor VIII-deficient patients? J Thromb Haemost 2006; 4:914.
41. Mauser Bunschoten EP, van Houwelingen JC, Sjamsoedin Visser EJM, van Dijken PJ, Kok AJ, Sixma JJ. Bleeding symptoms in carriers of hemophilia A and B. Thromb Haemost 1988; 59:349-352.
42. Plug I, Mauser-Bunschoten EP, Brö cker-Vriends AH, van Amstel HK, van der Bom JG, van Diemen-Homan JE, et al. Bleeding in carriers of hemophilia. Blood 2006; 108:52-56. (Pubitemid 43990612)
43. Mauser-Bunschoten EP. Symptomatic carriers of hemophilia: treatment of hemophilia monograph. World Federation of Hemophilia 2008; 46:1-17.
44. Ray JG. DDAVP use during pregnancy: an analysis of its safety for mother and child. Obstet Gynecol Surv 1998; 53:450-455.
45. Mannucci PM. Use of desmopressin (DDAVP) during early pregnancy in FVIII-deficient women. Blood 2005; 105:3382. (Pubitemid 40504365)